

## **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

### **PPJ Healthcare Enterprises, Inc.**

A Florida Corporation

401 E. Jackson Street, Suite 2340 Tampa, FL 33602

Phone (813) 723-1206 , Fax (866) 622-3215

Email: [info@ppjenterprise.com](mailto:info@ppjenterprise.com)

website: [www.ppjenterprise.com](http://www.ppjenterprise.com)

SIC Code: 7389 - Business services, misc.

### **FOR THE PERIOD ENDING JUNE 30, 2022**

OTC Markets Symbol: PPJE

As of June 30, 2022, the number of shares outstanding of our Common Stock was: 5,305,836,058

As of December 31, 2021, the number of shares outstanding of our Common Stock was 5,305,836,058

As of December 31, 2020, the number of shares outstanding of our Common Stock was: 4,840,836,058

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by a check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

### **1) Name and address(es) of the issuer and its predecessors (if any)**

PPJ Healthcare Enterprises, Inc. ("PPJE") formerly PPJ Enterprise until November 2014, formerly Healthcare Business Services Groups, Inc. (Nevada) until April 2008, formerly Winfield Financial Group, Inc. until December 2005, formerly Winfield Capital Group, Inc. Until March 2004.

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

The state of incorporation or registration of the issuer and each of its predecessors (if any) during the past five years. Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Florida. PPJE's current standing is active.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

No.

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

List of any stock split, stock dividend, recapitalization, merger, acquisition, spin off or reorganization either currently anticipated or that occurred within the past 12 months:

No.

The address (es) of the issuer's principal executive office:

401 East Jackson Street, suite 2340, Tampa, FL 33602.

The address(es) of the principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If the issuer or any of its predecessors have been the subject of such proceeding, please provide additional details in the space below:

## 2) Security Information

Trading symbol: PPJE

Exact title and class of securities outstanding: **Common Stocks**

CUSIP: No. 35369D505

Par or stated value: .0001

Total shares authorized: 8,000,000,000 as of date: 6/30/2022

Total shares outstanding: 5,305,836,058 as of date: 6/30/2022

Number of shares in the Public Float<sup>2</sup>: 4,660,836,058 as of date: 6/30/2022

Total number of shareholders of record: 119 as of date: 6/30/2022

**Class A Preferred Stocks**

CUSIP: No. 35369D505

Par or Stated value: \$10.00

Total shares authorized: Total 5,000,000 as of date: 6/30/2022  
shares issued: 0 as of date: 6/30/2022

---

Total shares outstanding: 0 as of date: 6/30/2022  
Number of shares in the Public Float 0 as of date: 6/30/2022

**Class B Preferred Stocks**

CUSIP: No. 35369D505

Par or Stated value: \$2.50

Total shares authorized: 50,000,000 as of date: 6/30/2022  
Total shares issued: 2,118,000 as of date: 6/30/2022  
Total shares outstanding: 0 as of date: 6/30/2022  
Number of shares in the Public Float 0 as of date: 6/30/2022  
Total number of shareholders of record: 5 as of date: 6/30/2022  
Number of shares in the Public Float 0 as of date: 6/30/2022

**Class E Preferred Stocks**

CUSIP: No. 35369D505

Par or stated value: .01

Total shares authorized: 100,000,000 as of date: 6/30/2022  
Total shares outstanding: 40,005,000 as of date: 6/30/2022  
Number of shares in the Public Float<sup>3</sup>: 0 as of date: 6/30/2022

Number of shares in the Public Float 0 as of date: 6/30/2022

**Non-Dilutive Common Stock**

CUSIP: No. 35369D505

Par or stated value:	<u>.0001</u>	
Total shares authorized:	8,000,000,000	as of date: 6/30/2022
Total shares outstanding:	0	as of date: 6/30/2022
Number of shares in the Public Float <sup>4</sup> :	0	as of date:6/30/2022

*All additional class(es) of publicly traded securities (if any): None*

Transfer Agent

Vstock Transfer, LLC  
 18 Lafayette Place  
 Woodmere, New York  
 11598 Phone: (212) 828-  
 8436 Ext. 124  
[www.VstockTransfer.com](http://www.VstockTransfer.com)  
 email:  
 shaindy@VstockTrsndfer.c  
 om

---

Is the Transfer Agent registered under the Exchange Act?<sup>5</sup> Yes: ☒ No: ☐

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u>  Date <u>12/31/2021</u> Common: 4,840,836,058  CLASS B Preferred: <u>2,118,000</u> Class E Preferred <u>40,005,000</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or canceled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (Entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Regulatory Type
2/25/2019	Returned to Treasury	3,400,000,000	Common	\$334,000	No	Chandana Basu	Lawsuit Liabilities	Restricted	Non
2/28/2019	Issuance	400,000,000	Common	\$4,000	Yes	GPL Ventures c/o Mr. Cosmin Panait	Illegal Conversion	Unrestricted	Section 3(a) the Secu Act
3/31/2019	Issuance	30,000,000	Class E Preferred	\$300,000	No	Chandana Basu	Lawsuit expenses	Restricted	Non

	Book Entry fraudulent	465,000,000	Common		no	Beaufort Capital LLC,  C/O Robert P. Marino /CEO/control person	Fraudu- lent transaction	Restricted	Company disputes
4/1/2021/ 2021									

4/5/2019	Issuance	180,000,000	Common	\$1,800	Yes	GPL Ventures c/o Mr. Cosmin Panait	Illegal Conversion		Section 3(a)(9) of the securities Act of 1933
Shares Outstanding on Date of This Report: None Issued.									
<u>Ending Balance:</u> 5,305,836,058									
Date <del>6</del> /30/2022 Common:									
<u>yes</u> Preferred: B 2,118,000									
<u>Preferred:</u> E 40,005,000									

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended December 31, 2019, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2017 through December 31, 2019 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of	Name of Noteholder (entities must have individual with voting	Reason for Issuance (e.g. Loan, Services,
-----------------------------	--------------------------------	---------------------------	-----------------------------	------------------	---	--	--

		Issuance (\$)			instrument to shares)	/ Investment control disclosed).	etc.)
12/31/2013	179,762	64,240(@20% plus \$2,000 fee per year)	97,653	12/30/2014	Default at 50% of 7 days average trading price	Jake Bhattacharya	Loan/litigation expenses
1/24/2014	50,000	paid	50,000	1/23/2015	Default at 50% of 7 days average trading price	Jhumur Bhattacharya	Loan/litigation expense

Use the space below to provide any additional details, including footnotes to the table above:

**Please Note: Beaufort Capital LLC. – Fraudulently manipulated Pacific Stock Transfer to book-entry 465,000,000 Common stocks for conversion without the Company’s consent after CEO Robert P. Marino and Beaufort Capital, LLC was charged by SEC. The Company terminated Pacific Stock Transfer Company for this reason in May 2021. Beaufort is barred by US Security to manipulate penny stocks for 5 years. Beaufort violated their agreement with the SEC. The Company is taking measures to reverse this book entry.**

**The Company secured \$500,000 loan guaranteed by CEO Chandana Basu. The Company will not disclose the name of the lender since it's Ms. Basu's direct liability and due to the active lawsuit and Janice shell's active and ongoing destruction to the Company's growth and Harassment of CEO Chandana Basu. Ms. Basu has active restraining order against Janice Shell, which Ms. Shell violated, Ms. Basu shall be seeking enforcement. Janice Shell is currently hiding at 2224 N. 1<sup>st</sup> Ave, Upland California in the second-floor window facing the street.**

7/12/2014	47,000	47,000	31,020	7/11/2015	Default at 40% of 7 day average trading price.	Anion Groups/ Rahul Chekuri	Loan/Litigation expenses
9/20/2014	78,841	78,841	0	9/3/2016	Promissory Note not convertible	Stuart Plaza	Unpaid lease
9/4/2019	10,750	10,000	2,400	9/3/2020	Promissory Note not convertible	Emerald Coast Capital/ Spencer Payne	Loan

**4) Financial Statements**

A. The following financial statements were prepared in accordance with: Financial Statements are incorporated by reference below. B.



U.S.

GAA

P ☐

IFRS

C. The financial statements for this reporting period were prepared by (name of individual)<sup>6</sup>:

Name: **Chandana Basu**  
Title: **CEO/PRESIDENT/CFO**  
Relationship to Issuer: **AFFILIATE**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet; 6/30/2022 posted on OTCIQ on 8/9/2022
- E. Statement of cash flows; 6/30/2022 posted on OTCIQ on 8/9/2022.
- F. Statement of Changes in Shareholders' Equity 6/30/2022 posted on OTCIQ on 8/9/2022.
- G. Financial notes; and 6/30/2022 posted on OTCIQ on 8/9/2022.
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").



If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## **5) Issuer's Business, Products and Services**

---

<sup>6</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

ISSUER IS IN MEDICAL BILLING SERVICE/REVENUE CYCLE MANAGEMENT BUSINESS AND HEALTHCARE PRACTICE MANAGEMENT SOFTWARE FOR ALL HEALTHCARE SPECIALTIES. ISSUER IS CURRENTLY DEVELOPING NATURAL HEALTH PRODUCTS TO MANUFACTURE AND SELL (R&D). RECENTLY ADDED CANNABIS/CBD PRODUCTS TO MARKET.

- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of such entity's business, contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

NONE.

- C. Describe the issuers' principal products or services, and their markets

THE COMPANY HAS BEEN IN THE MEDICAL BILLING BUSINESS SINCE 1990 PROVIDING SERVICES NATIONWIDE TO PHYSICIANS, FACILITIES AND ALL HEALTHCARE PROVIDERS.

## **6) Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If

the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Month to month for sales offices, outsourced billing, workers comp collection, software development lease space yearly renewal.

Please describe the company facilities. i.e. ~~Office locations~~, etc.

PPJE's corporate office located at 401 E. Jackson Street Suite 2340, Tampa, Florida 33602, the company has been in this location for close to 6 years month to month rent without a lease term. The Company outsources its services at this time. Office Rent is due on the 15<sup>th</sup> of each month. Employees working at home or vendor's location.

## 7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>CHANDANA BASU</u>	<u>Officer/Director/Owner of more than 5%</u>	<u>2225 N 1<sup>ST</sup> AVE, UPLAND, CA 91784</u>	<u>2,000,000</u>	<u>CLASS B PREFERRED</u>	<u>90%</u>	
<u>CHANDANA BASU</u>	<u>Officer/Director/Owner of more than 5%</u>	<u>2225 N 1<sup>ST</sup> AVE, UPLAND, CA 91784</u>	356,022,404	<u>Common</u>	<u>8%</u>	
CHANDANA BASU	<u>Officer/Director/Owner of more than 5%</u>	2225 N 1 <sup>ST</sup> AVE UPLAND CA 91784	30,000,000	CLASS E PREFERRED	74.9%	

--	--	--	--	--	--	--

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); **None**
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; **None**
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated; or **None on PPJ Healthcare Enterprises, but on CEO Ms. Basu for the company's liabilities:**

B. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. **None.**

9) Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. **None.**

## 10) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Jackson Morris, Tampa, FL.

Name: None

Accountant or Auditor **None at this time**

Investor Relations **None at this time**

Other Service Providers **None at this time**

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

## **11) Issuer Certification**

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Chandana Basu, certify that:

1. I have reviewed this Disclosure of PPJE for the period ending June 30, 2022.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, are fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/9/2022

/s/ Chandana Basu

CEO's Signature

*Principal Financial Officer:*

The issuer shall include certifications by the chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Chandana Basu, certify that:

1. I have reviewed this Disclosure of PPJE for the period ending June 30, 2022
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by

reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/9/2022

/s/ Chandana Basu CFO's

Signature

